Evidence map›Paper›PMID 40106056›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Multicenter phase II study on the efficacy of an oral nutritional supplement containing eicosapentaenoic acid in advanced gastric cancer patients with cachexia.

Ryohei Kawabata, Kazuhiro Nishikawa, Tomono Kawase, Junji Kawada, Yutaka Kimura, Yasushige Kashima, Shugo Ueda, Atsushi Takeno, Kazuhiro Shimomura, Hiroshi Imamura

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryohei KawabataDepartment of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, Osaka, 5938304, Japan. r-kawabata@umin.ac.jp.ORCID 0000-0001-7386-1096
Kazuhiro NishikawaDepartment of Surgery, Osaka General Medical Center, Osaka, Japan.
Tomono KawaseDepartment of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, Osaka, 5938304, Japan.
Junji KawadaDepartment of Surgery, Osaka General Medical Center, Osaka, Japan.
Yutaka KimuraDepartment of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, Osaka, 5938304, Japan.
Yasushige KashimaDepartment of Surgery, Tochigi Medical Center, Tochigi, Japan.
Shugo UedaDepartment of Gastroenterological Surgery, Kitano Hospital, Osaka, Japan.
Atsushi TakenoDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Kazuhiro ShimomuraDepartment of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
Hiroshi ImamuraDepartment of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, Osaka, 5938304, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCachexia is a common complication in advanced gastric cancer (AGC). Eicosapentaenoic acid (EPA) may ameliorate cachexia. This single-arm, phase II study assessed the potential benefit of an oral nutritional supplement containing EPA (ONS-EPA) for cachexia in AGC patients.

methodsChemotherapy-naive AGC patients with cachexia, defined by serum albumin < 3.5 g/dl and C-reactive protein ≥ 0.5 mg/dl, were included. Patients received an EPA-enriched supplement (Prosure

resultsOf 72 enrolled patients, 65 were evaluated. Median adherence was 42.8%. Median TTF in the PPS group was 4.8 months (95% CI 3.6-5.5), below the pre-set 4-month threshold. The PPS group had a higher proportion of patients who improved their nutritional and inflammatory status during treatment, along with better TTF and overall survival (OS) compared to those with poor adherence. Adjusted median TTF was 4.6 vs. 2.5 months (hazard ratio: 0.56; 95% CI 0.28-1.12, p = 0.105).

conclusionsAlthough the primary endpoint was not achieved, the study suggests that ONS-EPA may benefit AGC patients with cachexia.

Indexed as

CachexiaDietary SupplementsEicosapentaenoic AcidStomach NeoplasmsAdministration, OralAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedEicosapentaenoic AcidCachexiaEicosapentaenoic acidGastric cancer

Identifiers

PMID40106056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.